Key Takeaways
- Revenue surged 58% YoY, driven by new geographies and products: Nutraceuticals led segment growth at 137% YoY, while the base injectables business grew 52.9%.
- Margins are stable but thin, with PAT declining: EBITDA margin held nearly flat at 17.2%, but PAT margin fell to 9.8% from 12.3% YoY as new products launched with lower initial profitability.
- Two joint ventures will transform the business, but revenue is back-end loaded: The HAL JV adds a captive government buyer and a path to high-value therapies, while the Prague JV begins contributing profit from Q2 FY25.
- The IV market has a massive structural supply gap: India needs 768 crore bottles annually against a production capacity of only 510 crore, and the company's port proximity gives it a durable export cost advantage.
- What to watch next quarter: The Prague JV's commercial start and first revenue, the pace of Dehradun plant approvals from new regulators, and whether other expenses normalize from the Q4 spike of 36% of revenue.
Joint Ventures: The Structural Growth Bet
- HAL JV secures a captive, high-margin government channel: Sanjivani is the majority shareholder in a 13-year, renewable agreement with Hindustan Antibiotics Limited, where the government has verbally committed to buy the entire output at preferential PSU pricing (INR22 per bottle vs INR14-INR15 in open market tenders).
- Revenue timeline is back-end loaded: The HAL plant is expected to be operational by the end of Q3 FY25, contributing roughly one quarter of revenue in FY25 at a run-rate of around INR25 crores per quarter at 80% utilization.
- The real prize is a future product mix shift: Management plans to manufacture new therapies currently imported, which could shift pricing from INR17-INR20 per unit to INR90-INR100, though approvals and licenses will take 1.5 to 2 years.
- First right of refusal on expansion: If the government decides to expand capacity or set up a second plant, Sanjivani holds the first right to apply, creating a potential growth option beyond the initial facility.
- Prague JV adds immediate, unconsolidated profit: Sanjivani is a minority shareholder in Alivia Healthcare, with trial batches underway and complete operations expected by June; profit contribution of INR2.5 to INR3 crores is guided for full FY25, consolidated at the PBT level from Q2 FY25.
Srivardhan Khemka: "The trial batches are now on. The machines are under the performance check and we are expecting the complete operation to begin by the month of June."
IV Market Structure & Competitive Moat
- A structural demand-supply gap limits competitive intensity: India requires 768 crore bottles annually but has production capacity for only 510 crore, with scarcity concentrated in North India, Eastern India, and the Northeast.
- Port proximity is a durable cost moat: The Pune facility is 2.5 hours from JNPT port, a distance no other Indian IV plant matches, and since IV fluids are voluminous with high transportation costs, every plant can only supply competitively within a 300-400 km radius.
- Export customers are sticky and exclusive: Existing customers across 22 countries do not currently distribute IV fluids from any other company, and countries with plant approvals offer better pricing than markets like Nepal or Sri Lanka.
- PPP model pricing is structurally superior to open tenders: The government fixed INR22 per bottle for PSUs under the PPP model versus INR14-INR15 in open market tenders, a spread management attributes to the government's need to keep PSUs viable.
Ashwani Khemka: "We have an advantage because our plant is very near to the port which no plant in India is very near to the port. We are near to JNPT from our facility from Pune it is hardly 2.5 hours. Transportation cost plays a major role in this."
Product Portfolio & Profitability Dynamics
- Not all products are equally profitable, by design: Some products are profitable only during limited-duration shortages, some new products carry profitability for the first 2-3 years, and some are me-too products with thin margins; registration processes take over 2-3 years, after which all products are expected to contribute revenue and base-level profitability.
- New product margins start thin and expand: New products in initial phases carry lower margins, but these expand as supply chains get established; management expects overall margins to stay at 17-18% for FY25.
- The portfolio is broadening rapidly: The company added 15 new products in FY24, bringing the total count to 145, and plans to add another 15 to 20 products in the coming year.
Ashwani Khemka: "Every product cannot be profitable. Some are profitable to the duration of the time, availability and shortages. Some are perennially new products, which has a profitability for first two, three years. And some are me-too products."
Operational Scale-Up & Regulatory Upgrades
- Dehradun plant utilization is set to rise sharply: Currently operating at 40-45% capacity, utilization is expected to reach 65-70% in coming quarters as inspections from African and Latin American markets are triggered.
- Both plants are being upgraded to global GMP standards: Upgradation is underway to meet updated Schedule M requirements (now at WHO GMP level) and standards at par with PIC/S and EU GMP, involving additions of technical people, testing equipment, and production equipment.
- Revenue from these upgrades is a next-year story: Management stated that revenue expansion from plant upgradations will be seen in the next financial year, while current-year growth will come from existing markets.
- Regulatory approvals are expanding the addressable market: The company is entering PIC/S markets and pursuing Latin American approvals, with 2-3 Latin American countries already secured.
Financials: Costs, Margins & Balance Sheet
- Q4 other expenses spiked on one-time regulatory costs: Other expenses jumped to 36% of revenue in Q4 due to inspection costs, audit costs, registration costs that were not capitalized, and initial sampling and validation testing charges; management expects the full-year ratio to normalize to nearly the same level as prior years.
- Red Sea disruptions inflated inventory and receivables: The Red Sea situation reduced vessel frequency from weekly to once every 10-15 days, causing container shortages and a buildup of inventory.
- Capex is modest relative to the growth agenda: FY25 capex is guided at INR6-INR8 crores for the Dehradun and Navi Mumbai plants, while the HAL JV involves a total capex of INR35 crores (60% Sanjivani's share), to be capitalized in the current year as an ongoing process.
- Tax rate is guided at 25-26% for FY25.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Prague JV commercial start | Complete operations begin, revenue recognition starts | June (Q2 FY25) |
| Prague JV profit contribution | INR2.5 to INR3 crores consolidated at PBT level | Full FY25 |
| HAL JV plant operational | Plant commercialized | End of Q3 FY25 |
| HAL JV revenue contribution | One quarter of revenue at ~INR25 crores run-rate (80% utilization) | Q4 FY25 |
| Base business revenue growth | 20-25% growth | FY25 |
| Consolidated top line | Around INR90 crores (including one quarter of HAL) | FY25 |
| Consolidated bottom line | INR12 to INR13 crores (including Prague contribution) | FY25 |
| EBITDA margin | Stay at 17-18% | FY25 |
| Dehradun capacity utilization | Rise to 65-70% | Coming quarters and next financial year |
| Product additions | 15 to 20 new products | Coming year |
| Capex (Dehradun + Navi Mumbai) | INR6 to INR8 crores | FY25 |
| Tax rate | 25-26% | FY25 |
Key Metrics
| Metric | Q4 FY24 |
|---|---|
| Revenue | ₹12.86 cr, +58% YoY |
| EBITDA margin | 17.2%, vs 17.1% in Q4 FY23 |
| Net profit | ₹1.26 cr, +26% YoY |
| PAT margin | 9.8%, vs 12.3% in Q4 FY23 |
| Injectable segment revenue growth | 52.9% YoY |
| Oral segment revenue growth | 66.2% YoY |
| Nutraceuticals revenue growth | 137% YoY |
| Revenue mix | 30% domestic, 70% exports |
| Full-year FY24 revenue | ₹54.4 cr, +53% YoY |
| Full-year FY24 EBITDA | ₹8.76 cr, vs ₹6.19 cr in FY23 |
| Total product count | 145 as of Mar 31, 2024; 15 new products added in FY24 |
| New geographies entered in FY24 | 6 |
| Dehradun plant capacity utilization | 40% to 45% currently, expected to reach 65%–70% in coming quarters |
| Active registrations | ~180, filing 15–20 every quarter |
| FY25 consolidated revenue guidance | ~₹90 cr top line, 20%–25% base business growth |
| FY25 consolidated bottom-line guidance | ₹12–13 cr, including Prague profit contribution of ₹2.5–3 cr |
| HAL JV FY25 revenue estimate | ₹20–25 cr for one quarter, ~18% EBITDA margin |
| Tax rate guidance for FY25 | 25%–26% |